SERPINA4 Antibody

What is SERPINA4/kallistatin and what biological functions make it relevant for research?

SERPINA4, commonly known as kallistatin, was first identified as a tissue kallikrein-binding protein in the early 1990s. It represents a multifunctional serpin family protein primarily expressed in the liver and secreted into circulation. The protein exerts significant effects inhibiting tumor growth and angiogenesis across multiple malignancies . Its biological significance stems from its ability to suppress angiogenesis through inhibition of TNF-α-induced NF-κB activation and by blocking VEGF signaling pathways, effectively inducing apoptosis in cultured human endothelial cells . Additionally, SERPINA4 directly inhibits cancer cell proliferation, migration, and invasion by regulating cancer cell signaling in malignancies including lung, breast, and hepatocellular carcinoma . These properties make SERPINA4 antibodies valuable tools for studying tumor suppression mechanisms and vascular biology.

What are the standard techniques for detecting SERPINA4 in experimental samples?

Multiple techniques have proven effective for SERPINA4 detection in research applications:

• Quantitative Real-Time PCR (qRT-PCR): For measuring SERPINA4 mRNA expression levels using primers such as:

  • Forward: 5'-CGAGCTGTCTGAGTCCGATG-3'

  • Reverse: 5'-GCCCACAGTGTCGTAGAAGTT-3'

• Western Blotting: For protein detection, typically using:

  • Primary antibody: Anti-SERPINA4 (1:2000 dilution)

  • Protein separation: 10% SDS-PAGE

  • Membrane: PVDF

  • Blocking: 5% fat-free milk with 0.1% Tween-20

• Immunohistochemistry (IHC): For tissue localization studies:

  • Antibody dilution: 1:300

  • Antigen retrieval: Citrate buffer (0.01 M, pH 6.0)

  • Visualization: EnVision two-step Visualization System

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative measurement of SERPINA4 in serum/plasma samples, using monospecific antibodies as capture antibodies

Each method offers different advantages depending on your research question and available samples.

How can researchers optimize SERPINA4 immunohistochemistry protocols for different tissue types?

Optimizing SERPINA4 immunohistochemistry requires consideration of several key parameters:

Tissue Preparation and Antigen Retrieval:

• Paraffin-embedded sections should undergo complete dewaxing and rehydration

• Heat-induced epitope retrieval using citrate buffer (0.01 M, pH 6.0) has proven effective for SERPINA4 detection

• Incubation time in boiling buffer may require optimization (typically 10-20 minutes)

Antibody Selection and Dilution:

• Primary antibody dilution typically ranges from 1:300 to 1:500 depending on antibody source and tissue type

• Overnight incubation at 4°C generally provides optimal results

• Secondary detection systems like EnVision two-step visualization should be incubated for 30 minutes at room temperature

Scoring and Interpretation:
Implement a structured scoring system for consistent results:

• Staining intensity: 0 (none), 1 (weak), 2 (moderate), 3 (strong)

• Staining area: 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%), 4 (76-100%)

• Final score calculation: intensity score × area score

For comparative studies between normal and pathological tissues, having two independent researchers evaluate the slides blindly enhances reliability.

What are the critical considerations for developing a quantitative ELISA for SERPINA4/kallistatin?

Developing a reliable quantitative ELISA for SERPINA4 requires addressing several technical challenges:

Antibody Selection:

• Use monospecific antibodies as capture antibodies to ensure specificity

• Rule out cross-reactivity with other SERPIN family proteins through western blot validation

Assay Validation Parameters:

• Specificity validation: Test against other SERPIN family proteins to confirm lack of cross-reactivity

• Precision determination: Establish both inter- and intra-assay precision (coefficient of variation typically <15%)

• Linearity assessment: Use spiked samples with serial dilutions to define linear range

• Recovery testing: Add known amounts of recombinant SERPINA4 to samples and verify recovery percentages

Reference Range Establishment:

• Collect samples from healthy controls to establish normal reference intervals

• Age and gender-based stratification may be necessary for accurate interpretation

The developed ELISA should be sensitive enough to detect picogram/ml concentrations, which are typical physiological levels of circulating SERPINA4/kallistatin.

How does SERPINA4 expression change in malignancies and what are the implications for using it as a biomarker?

SERPINA4 expression undergoes significant alterations in malignancies, particularly demonstrated in colorectal cancer:

Expression Pattern Changes:

• Quantitative real-time PCR analysis reveals significantly decreased SERPINA4 mRNA expression in colorectal cancer specimens compared to adjacent normal mucosa

• Western blot analysis confirms this decrease at the protein level

• Immunohistochemistry shows altered distribution patterns:

  • In normal colorectal mucosa: 15.0% negative, 35.2% weak, 49.8% strong SERPINA4 expression

  • In colorectal cancer: 50.5% negative, 32.7% weak, 16.8% strong SERPINA4 expression

Clinical Correlations:
Decreased SERPINA4 expression significantly associates with:

• Greater invasion depth

• Nodal involvement

• Distant metastasis

• Advanced AJCC stage

• Poor tumor differentiation

Prognostic Value:
SERPINA4 serves as an independent prognostic indicator for:

These findings suggest SERPINA4 represents a potential biomarker for cancer progression and prognosis, warranting further investigation into its utility in diagnostic panels.

What cell-based assays can effectively demonstrate SERPINA4's functional effects?

Several cell-based assays have proven effective for investigating SERPINA4's functional impact on cellular processes:

Proliferation Assays:

• Cell Counting Kit-8 (CCK-8) assays can measure the effect of SERPINA4 overexpression on cancer cell proliferation

• Typical protocol includes:

  • Plating cells in triplicate (2 × 10³ cells/well)

  • Measuring absorbance at 450 nm at multiple timepoints (12, 24, 48, and 72 h)

  • Incubating with CCK-8 solution for 2 h at 37°C

Migration and Invasion Assays:

• Transwell assays with or without Matrigel coating evaluate SERPINA4's impact on cancer cell motility

• Wound healing assays provide complementary data on cell migration capacity

Signal Pathway Analysis:

• Western blotting for downstream effectors after SERPINA4 overexpression or knockdown

• Particular focus on VEGF signaling pathway components and NF-κB activation markers

Angiogenesis Models:

• Tube formation assays using HUVEC cells treated with conditioned media from SERPINA4-manipulated cells

• Chorioallantoic membrane (CAM) assays for in vivo angiogenesis evaluation

These complementary approaches provide a comprehensive assessment of SERPINA4's multifaceted functions in cancer biology.

What are the optimal methods for validating SERPINA4 antibody specificity?

Ensuring antibody specificity is crucial for obtaining reliable research results. For SERPINA4 antibodies, comprehensive validation should include:

Western Blot Validation:

• Test antibody against recombinant SERPINA4 protein

• Include positive control tissues (liver samples)

• Include negative control tissues (tissues known to have low expression)

• Test against other SERPIN family members to rule out cross-reactivity

Knockdown/Overexpression Verification:

• Compare antibody signal between wild-type cells and those with SERPINA4 knockdown

• Verify signal increase in SERPINA4 overexpression systems

• Quantify the correlation between mRNA and protein levels detected

Peptide Competition Assays:

• Pre-incubate antibody with immunizing peptide/protein

• Observe elimination of specific signals while non-specific binding remains

Immunoprecipitation-Mass Spectrometry:

• Immunoprecipitate samples using the SERPINA4 antibody

• Confirm identity of captured proteins by mass spectrometry

• Validate that SERPINA4 is the predominant protein identified

A multi-method validation approach ensures the antibody's reliability for subsequent experimental applications.

How can SERPINA4 levels serve as biomarkers for liver function and chronic liver disease?

SERPINA4/kallistatin shows promising utility as a biomarker for liver dysfunction and chronic liver disease (CLD):

Biological Rationale:

• SERPINA4 is primarily expressed by the liver and secreted into circulation

• Decreasing blood concentrations reflect diminishing liver function

• Quantitative changes correlate with disease progression

Clinical Findings:

• Studies demonstrate reduced levels of SERPINA4/kallistatin in patients with chronic liver disease compared to healthy controls

• The magnitude of reduction correlates with disease severity

Methodological Approach:

• ELISA provides the most accurate quantification of serum/plasma SERPINA4 levels

• Sample handling is critical: standardized collection, processing, and storage protocols

• Inter-individual variability requires established reference ranges stratified by age and sex

Advantages Over Conventional Markers:

• Potentially higher sensitivity for early-stage disease detection

• May reflect functional impairment before structural changes become apparent

• Could serve as part of a multi-marker panel improving diagnostic accuracy

Further large-scale clinical studies are needed to establish definitive cut-off values and validate SERPINA4's position in clinical diagnostic algorithms for liver diseases.

What is the current understanding of SERPINA4's mechanism in tumor suppression?

SERPINA4 exhibits tumor suppressive properties through multiple complementary mechanisms:

Anti-angiogenic Effects:

• Inhibits angiogenesis by antagonizing VEGF signaling pathway

• Blocks endothelial cell proliferation, migration, and invasion

• Induces apoptosis in cultured human endothelial cells

• Suppresses TNF-α-induced NF-κB activation

Direct Anti-tumor Effects:

• Directly inhibits cancer cell proliferation

• Reduces migration and invasion capacity

• Modulates cancer cell signaling pathways across multiple malignancies, including lung, breast, and hepatocellular carcinoma

Experimental Evidence:

• Xenograft tumor models in mice show growth inhibition with SERPINA4 treatment

• In vitro studies demonstrate reduced cell proliferation via Cell Counting Kit-8 (CCK-8) assays

• Clinical samples reveal inverse correlation between SERPINA4 expression and aggressive tumor characteristics in colorectal cancer

Translational Implications:

• The multifaceted mechanisms suggest SERPINA4 or its derivatives could serve as potential therapeutic agents

• Expression levels may function as prognostic indicators, with decreased expression correlating with poorer outcomes

Understanding these mechanisms provides foundations for developing targeted therapeutic approaches that either restore SERPINA4 levels or mimic its tumor suppressive functions.

How can researchers address common issues when working with SERPINA4 antibodies in western blotting?

When troubleshooting SERPINA4 detection in western blotting, researchers should consider several technical parameters:

Sample Preparation Optimization:

• Use RIPA Lysis Buffer with protease inhibitors for optimal protein extraction

• Standardize protein quantification using BCA protein assay

• Load adequate protein amounts (typically 30 μg per lane)

• Heat samples at 95°C for 5 minutes in reducing sample buffer

Electrophoresis Conditions:

• Use 10% SDS-PAGE for optimal resolution

• Run at constant voltage (typically 100-120V)

• Ensure complete protein transfer to PVDF membranes using adequate transfer time

Antibody Incubation Parameters:

• Block membranes thoroughly in 5% fat-free milk with 0.1% Tween-20

• Optimize primary antibody dilution (typically 1:2000 for SERPINA4)

• Incubate primary antibody at 4°C overnight for best results

• Use HRP-conjugated secondary antibodies at appropriate dilutions (1:5000 recommended)

Common Issues and Solutions:

• High background:

  • Increase blocking time or concentration

  • Reduce antibody concentration

  • Add 0.05-0.1% Tween-20 to washing buffers

• Weak signal:

  • Increase protein loading

  • Extend primary antibody incubation time

  • Use more sensitive detection reagents

• Multiple bands:

  • Verify antibody specificity

  • Add protease inhibitors to prevent degradation

  • Optimize sample preparation to prevent protein aggregation

Systematic optimization of these parameters will significantly improve SERPINA4 detection in western blotting applications.

What are the most promising future directions for SERPINA4 research?

Based on current understanding, several promising research directions for SERPINA4 warrant further investigation:

Biomarker Development:

• Validation of SERPINA4 as a diagnostic/prognostic biomarker for chronic liver diseases through large-scale clinical studies

• Integration into multi-marker panels to improve diagnostic accuracy

• Development of point-of-care testing for rapid assessment of SERPINA4 levels

Cancer Therapeutics:

• Design of SERPINA4-based peptides or mimetics targeting its tumor-suppressive functions

• Exploration of SERPINA4 gene therapy approaches for cancers with decreased expression

• Combination strategies leveraging SERPINA4's anti-angiogenic properties with existing cancer treatments

Methodological Advances:

• Development of higher-sensitivity assays detecting physiological SERPINA4 concentrations in the picogram/ml range

• Creation of conditional knockout models to further elucidate tissue-specific functions

• Application of systems biology approaches to map SERPINA4's position in broader signaling networks

Mechanistic Understanding:

• Further delineation of the molecular interactions between SERPINA4 and VEGF signaling components

• Investigation of potential epigenetic regulation of SERPINA4 expression in different pathological states

• Exploration of SERPINA4's role in inflammatory processes beyond cancer and liver disease